The designation FLJ20433 inhibitors would likely refer to a group of compounds designed to specifically inhibit the activity of a protein encoded by a gene initially labeled as FLJ20433. The FLJ prefix typically arises from a gene cataloging system and stands for Full-Length Japanese, indicating that the gene was identified during large-scale cDNA sequencing projects primarily conducted in Japan. These identifiers were often assigned to genes for which little functional information was available at the time of discovery. As such, the FLJ20433 protein would be presumed to have some biological activity or function that could be modulated by small molecules. However, without a clearly established biological role or even a well-understood molecular function, the development of inhibitors targeting such a protein would be in the preliminary stages of research.
In the case that FLJ20433 has been characterized and there is an interest in modulating its activity, the development of inhibitors would begin with a detailed understanding of the protein's structure and function. Researchers would first seek to determine its role within cellular processes, its three-dimensional structure, and the key domains that are critical for its activity. Techniques such as X-ray crystallography, cryo-electron microscopy, or NMR spectroscopy could be used to elucidate the protein's structure, revealing potential binding sites for inhibitors. These sites could include active sites, allosteric sites, or interfaces that are important for the protein's interaction with other cellular components. Once potential binding sites have been identified, the process of inhibitor design can commence, with the goal of producing molecules that can bind to FLJ20433 with high specificity and affinity.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
Intercalates DNA and interferes with RNA polymerase function, which can inhibit transcription. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Inhibits topoisomerase I, leading to DNA damage and potentially affecting transcription. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Intercalates into DNA and RNA, which can disrupt DNA replication and RNA transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Intercalates into DNA and inhibits RNA polymerase, leading to decreased mRNA synthesis. | ||||||
Quercetin | 117-39-5 | sc-206089 sc-206089A sc-206089E sc-206089C sc-206089D sc-206089B | 100 mg 500 mg 100 g 250 g 1 kg 25 g | $11.00 $17.00 $108.00 $245.00 $918.00 $49.00 | 33 | |
A flavonoid that may affect gene expression by modulating various signaling pathways. | ||||||
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Inhibits inosine monophosphate dehydrogenase, potentially affecting RNA and DNA synthesis. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $142.00 $558.00 | 4 | |
Interacts with DNA and can inhibit various DNA and RNA polymerases. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
Inhibits translation initiation and could decrease protein synthesis. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Inhibits peptidyl transferase activity in eukaryotic ribosomes, affecting protein synthesis. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Forms cross-links in DNA, inhibiting DNA synthesis and thus affecting gene expression. | ||||||